Henry Schein Reports Strong 2026 Third Quarter and Raises FY2026 Guidance
Henry Schein reported Q3 2026 earnings with GAAP EPS up 26.2% YoY and non-GAAP EPS up 13.0% YoY. Total sales grew 4.0%, driven by U.S. dental merchandise sales. The company raised FY2026 guidance for non-GAAP EPS to $5.56 and adjusted EBITDA growth to high-single-digits.
How this was made
The 30-second read
Why it matters
Guidance lift is likely to drive short‑term buying interest and may set a higher earnings baseline for the year.
Market read
The earnings beat and guidance raise are material for investors in health‑care distribution and could influence sector ETFs.
What to watch
Potential headwinds from foreign‑currency volatility and limited growth‑investment cap.
Background
Henry Schein reported Q3 2026 results with 4% sales growth and raised FY2026 guidance.
Ticker impact
Henry Schein raised FY2026 non‑GAAP EPS guidance to $5.50 and adjusted EBITDA outlook, after reporting Q3 2026 results.
likely upward pressure as investors price in higher earnings expectations
Guidance lift is material and new; market typically reacts positively to raised EPS forecasts for a mid‑cap health‑care distributor.
Market effects
May boost sentiment for health‑care distribution and dental equipment suppliers.
U.S. market focus; limited immediate effect on other regions.
Modest, confined to sector and peers.
Counterpoint
If the guidance assumes continued tariff refunds, any reversal could hurt future results.
Key entities
- CompanyHenry Schein, Inc.
U.S. health‑care products distributor (NASDAQ: HSIC).
